In last trading session, Mineralys Therapeutics Inc (NASDAQ:MLYS) saw 0.34 million shares changing hands with its beta currently measuring 1.46. Company’s recent per share price level of $9.56 trading at $0.03 or 0.31% at ring of the bell on the day assigns it a market valuation of $476.43M. That closing price of MLYS’s stock is at a discount of -76.88% from its 52-week high price of $16.91 and is indicating a premium of 10.25% from its 52-week low price of $8.58.

For Mineralys Therapeutics Inc (MLYS), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 2 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -1.08 in the current quarter.

Mineralys Therapeutics Inc (NASDAQ:MLYS) trade information

Upright in the green during last session for gaining 0.31%, in the last five days MLYS remained trading in the red while hitting it’s week-highest on Tuesday, 02/18/25 when the stock touched $9.56 price level, adding 11.07% to its value on the day. Mineralys Therapeutics Inc’s shares saw a change of -22.34% in year-to-date performance and have moved -6.27% in past 5-day. Mineralys Therapeutics Inc (NASDAQ:MLYS) showed a performance of -6.18% in past 30-days.

Wall Street analysts have assigned a consensus price target of 30 to the stock, which implies a rise of 68.13% to its current value. Analysts have been projecting 30 as a low price target for the stock while placing it at a high target of 30. It follows that stock’s current price would drop -213.81% in reaching the projected high whereas dropping to the targeted low would mean a loss of -213.81% for stock’s current value.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -170.42% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -7.97% while estimates for its earnings growth in next 5 years are of -2.10%.

On the other hand, iShares Russell 2000 ETF and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Nov 30, 2024 , the former fund manager was holding 807.86 shares of worth $7.72 million or 1.62% of the total outstanding shares. The later fund manager was in possession of 784.65 shares on Sep 30, 2024 , making its stake of worth around $7.5 million in the company or a holder of 1.57% of company’s stock.